a For included studies, number of PTS events as assessed by Villalta s criteria b Low number of events. c There were 3 studies originally included for this outcome (Brandjes et al,103 Prandoni et al,104 and Kahn et al106 [SOX]). There was very high heterogeneity among the 3 studies, I2 92% (P < .01). The pooled effect of the 3 studies was RR, 0.63 (0.35-1.13). Yet, because of the high risk of bias associated with Brandjes et al103 and Prandoni et al,104 it was decided to focus on the estimate of the low-risk trial, Kahn et al106 (SOX), which is used here. d This estimate is based on the ndings of the VETO study.232 e CI includes values suggesting no effect and values suggesting either bene t or harm. f There were 3 studies originally included for this outcome (Brandjes et al,103 Prandoni et al,104 and Kahn et al106 [SOX]). The pooled effect of the 3 studies was RR, 0.91 (0.65-1.27). Yet, because of the high risk of bias associated with Brandjes et al103 and Prandoni et al,104 it was decided to focus on the estimate of the low-risk trial, Kahn et al106 (SOX), which is used here. g This estimate is the mean of 2 estimates derived from 2 studies: 12.4% probable/de nite VTE170 h Wide CI that includes no effect. i Estimate derived from Kahn et al.107 j Estimate based on VEINES-QOL score improvement of 5.8 points (SD, 7.5) for active ECS vs 5.9 (SD, 7.1) for placebo ECS. k SF-36 physical component score improved by 8.4 points (SD, 13.6) for active ECS vs 9.9 (SD, 13.2) for placebo ECS (difference between groups of -1.53 points, 95% CI, -3.44 to 0.39; P .12). 